CBP-307 is an orally-active small molecule modulator of S1P1, a G-protein coupled receptor on the surface of certain populations of T cells. CBP-307 works by causing internalization of S1P1, known to be critical for T cell trafficking into inflamed tissues. This drug candidate is designed to avoid the side effects on cardiovascular, lung and liver functions that are known for a marketed, first-generation drug targeting the same receptor. Based on our clinical data, we believe this compound has the potential to be far superior to the first-generation compound and has advantages over other second-generation compounds now in various stages of development. 

CBP-307 has been evaluated in 74 healthy volunteers in two phase 1 clinical trials (Australia and China) with single and repeat dosing. In these studies, the drug exhibited potent T cell modulation activity while it was found to be safe and well tolerated. IND application in China was approved for clinical trials on 5 indications (i.e. Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis, Psoriasis, and Multiple Sclerosis) by CFDA in January 2017. Phase II trials in ulcerative colitis and Crohn's disease are currently underway.

TEL/FAX: 0512-53577866

E-MAIL: qchang@connectpharm.com

ADD: Science and Technology Park, East R&D Building , 3rd Floor , 6 Beijing West Road, Taichang, Jiangsu, China 215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.

Technical support: Epower